Menopause Telehealth Provider Costs

Direct answer

Menopause telehealth costs can look very different depending on whether a provider publishes medication-only prices, requires a recurring membership, bundles clinician care and medication into one HRT program, or discounts longer treatment terms. RightFit’s current research separates estradiol and progesterone formulations, program fees, included services, and additional hormone costs so a low starting medication price is not compared directly with a bundled monthly care program without context.

Estradiol market snapshot

Progesterone market snapshot

Current providers illustrate three different pricing models

Mochi currently publishes separate starting medication prices for estradiol tablet, estradiol patch, and progesterone while requiring a recurring membership. Henry publishes a broader monthly HRT program amount across eligible hormone options. Effecty publishes formulation-specific estradiol prices with lower effective rates for a twelve-month supply purchase.

These are all valid commercial structures, but they should not be compared as though the headline dollar figure purchases the same thing. RightFit keeps the source pricing model intact and shows the additional required components separately.

Medication-plus-membership pricing can make a low starting price incomplete

A medication starting price can be useful for comparing the drug component, but it is not the complete recurring program cost when a membership is required. Mochi’s current HRT structure demonstrates this clearly. RightFit preserves the medication amount and membership separately rather than rewriting them into a provider number that was never published.

Bundled HRT programs can include more services

Henry’s current menopause/HRT materials use a bundled monthly program model that includes eligible hormone-treatment options and core telehealth services. If testosterone is prescribed, the provider publishes an additional charge. RightFit keeps that conditional add-on separate from the base program amount.

Long-term pricing can lower the monthly equivalent

Effecty currently publishes lower effective estradiol prices for a twelve-month supply purchase. Those amounts can make the monthly rate look significantly lower than the ordinary monthly price, but the customer is accepting a longer financial commitment. RightFit therefore keeps term-dependent prices separate from the normal recurring rate.

Formulation changes what a price represents

An estradiol tablet, patch, and cream are different formulations. Progesterone can also appear in oral or compounded topical forms. A market report that combines them without labels would make unlike products look directly comparable. RightFit preserves formulation and route before calculating or interpreting market summaries.

FDA-approved and compounded hormone products should remain distinct

FDA’s current menopause guidance states that FDA-approved hormone therapies are available for menopause and distinguishes them from compounded products marketed as bioidentical hormones. RightFit therefore keeps preparation type visible where the provider source establishes it and does not use the word bioidentical as evidence of FDA approval or superior safety.

The 2026 labeling updates make current regulator sourcing important

FDA approved prescribing-information changes for multiple menopausal hormone-therapy products in 2026. Those changes do not make every hormone product’s label identical, but they reinforce the need to use current product-specific and FDA sources rather than relying on older generalized warning language.

Progesterone pricing adds another provider comparison layer

Current RightFit data includes progesterone programs from Henry, Mochi, and NavioMD using different commercial structures. Henry includes progesterone options inside its bundled HRT model, Mochi publishes a medication price plus membership, and NavioMD has a compounded oral progesterone program with its own subscription terms. RightFit keeps those models separate rather than forcing one progesterone market price.

Additional medications can change the total

A menopause care plan can involve more than one hormone depending on the clinician-selected treatment. If another medication carries an additional published charge, RightFit keeps that cost separate instead of silently adding it to every HRT program. This prevents one optional or conditional component from inflating the apparent base price for all patients.

Labs can be part of the care path without one universal price

Providers may use laboratory testing as part of hormone evaluation or monitoring, but not every public page states the same lab requirement or fee. RightFit leaves the lab field unresolved unless the provider clearly publishes the commercial term. A missing lab price is not treated as zero and is not estimated from another provider.

Shipping can be bundled or left unclear

Some current HRT records explicitly include shipping, while other provider pages focus on medication and membership without a clear shipping statement. RightFit records an inclusion only when the source supports it and keeps silence as unknown.

State availability can differ by formulation and provider

A telehealth company’s broad footprint does not automatically prove that every estradiol or progesterone formulation is available in every state. Prescriber licensure, pharmacy reach, formulation, and provider policy can all affect access. RightFit publishes state coverage only where program-specific evidence supports it.

What this cost report measures

• Exact hormone and formulation.
• Medication price or bundled HRT program price.
• Required recurring membership or care fee.
• Normal versus term-dependent pricing.
• Billing period and commitment.
• Included clinician access and shipping when verified.
• Lab fees or inclusions when clearly published.
• Additional medication charges when provider terms identify them.
• Program-level state availability when verified.
• Provider-primary source and current verification date.

What the report does not combine blindly

• Medication-only price and bundled care price.
• Tablet, patch, cream, and capsule formulations.
• Normal monthly rates and twelve-month effective rates.
• FDA-approved hormone products and compounded products.
• Base HRT program price and conditional testosterone or other add-ons.
• Published lab costs and unknown lab costs.
• Provider-wide availability and program-specific state evidence.

Why a simple provider ranking would be misleading

One provider can look cheaper because it publishes medication separately, while another can look more expensive because its price includes clinician access and shipping. A third can show the lowest monthly equivalent only when the customer prepays for a year. Those are different commercial tradeoffs, not one universal best-value ranking.

Why source hierarchy matters

Provider pages are the primary source for current program price and inclusions. FDA and current official labels are stronger for approval status and regulatory context. RightFit keeps those sources in their appropriate roles and refreshes them independently when commercial terms or federal labeling change.

Questions a reader can use

• What exact hormone and formulation is priced?
• Is the amount medication-only or a bundled program?
• Is a membership required?
• Does the lowest rate require a longer commitment?
• Are clinician visits and shipping included?
• Are labs included, separate, or unknown?
• Could another prescribed hormone add a separate charge?
• Is the exact formulation verified in my state?
• Is the product FDA-approved or compounded?
• When was the provider information last checked?

What this report cannot decide

The menopause cost report does not determine whether hormone therapy is appropriate for a particular person or which hormone, formulation, or treatment duration should be used. Those are individualized healthcare decisions. The report is intentionally limited to public pricing, program structure, product identity, and source context.

Bottom line

Menopause telehealth costs vary because providers structure hormone care differently. Mochi separates medication from membership, Henry uses a bundled HRT model, Effecty publishes formulation-specific prices with longer-term discounts, and NavioMD adds another progesterone subscription structure. RightFit keeps those differences, current FDA context, and unknown costs visible so readers can understand what each price actually represents.

Why the lowest starting medication price should not define the provider

A provider can advertise a low starting medication amount while requiring membership, follow-up care, or other recurring services separately. Another provider can publish one higher bundled amount that covers care and medication options. The menopause report therefore avoids labeling a provider cheapest from one line item. The comparison needs the pricing model and required components before the difference is meaningful.

Why cost reporting should distinguish base, conditional, and unknown amounts

The base amount is the provider’s ordinary medication or program price. A conditional amount can depend on a twelve-month purchase or an additional hormone being prescribed. Unknown costs include items such as labs when no universal public price is stated. RightFit keeps those categories separate so a report does not turn conditions or missing information into one falsely precise total.

A dated market report should not become a permanent price promise

Menopause telehealth providers can change membership fees, formulation prices, included services, or long-term discounts without changing the name of the HRT program. The report therefore depends on verification dates and live structured rows. Its explanatory methodology can remain stable while the underlying commercial observations are refreshed as provider terms change.

Verification dates keep that market snapshot appropriately time-bound.